https://www.selleckchem.com/pr....oducts/napabucasin.h
01). The same trend was observed in peripheral platelets from AD patients versus controls (Bmax of 214±17 versus 95±4 fmol/mg of proteins, respectively, p 0.01). AD subjects show significantly higher A2A receptor density than controls. Values on platelets seem to correlate with those in the brain supporting a role for A2A receptor as a possible marker of AD pathology and drug target for novel therapies able to modify the progression of dementia. AD subjects show significantly higher A2A receptor density than controls. Values on
Like
Comment
Share
